You just read:

Overall Share of Ocrevus Remains Stable Among Recent New Start Patients, Yet Genentech's Efforts to Increase First-Line Use Appears to be Paying Off in the Dominant Relapsing-Remitting Multiple Sclerosis Subgroup

News provided by

Spherix Global Insights

Feb 11, 2020, 08:00 ET